{
    "clinical_study": {
        "@rank": "141496", 
        "arm_group": {
            "arm_group_label": "Treatment (bortezomib)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive PS-341 IV over 3-5 seconds twice weekly on weeks 1 and 2. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell\n      growth. Phase II trial to study the effectiveness of PS-341 in treating women who have\n      metastatic breast cancer"
        }, 
        "brief_title": "PS-341 in Treating Women With Metastatic Breast Cancer", 
        "condition": [
            "Recurrent Breast Cancer", 
            "Stage IV Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Determine the efficacy of PS-341, in terms of response rate, in women with metastatic\n      breast cancer.\n\n      SECONDARY OBJECTIVES:\n\n      I. Determine the clinical activity of this drug, in terms of progression-free survival, in\n      these women.\n\n      II. Determine the toxicity profile and tolerability of this drug in these women.\n\n      III. Determine the pharmacodynamics of this drug in these women.\n\n      OUTLINE:\n\n      Patients receive PS-341 IV over 3-5 seconds twice weekly on weeks 1 and 2. Courses repeat\n      every 3 weeks in the absence of disease progression or unacceptable toxicity.\n\n      PROJECTED ACCRUAL: A maximum of 12-35 patients will be accrued for this study within 9-12\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed invasive breast cancer\n\n               -  Clinical and/or radiological evidence of stage IV disease\n\n          -  Relapsed or resistant disease within 6-12 months after completion of prior\n             chemotherapy with doxorubicin or epirubicin and/or paclitaxel or docetaxel\n             foradvanced disease or in the adjuvant setting\n\n          -  At least 1 unidimensionally measurable lesion\n\n               -  At least 20 mm by conventional techniques\n\n               -  At least 10 mm by spiral CT scan\n\n               -  No bone metastases as only measurable site\n\n               -  Pleural or peritoneal effusions not acceptable as measurable disease\n\n          -  No known brain metastases\n\n          -  Hormone receptor status:\n\n               -  Estrogen receptor-negative\n\n               -  Estrogen receptor-positive\n\n          -  Female\n\n          -  Performance status - ECOG 0-2\n\n          -  Performance status - Karnofsky 60-100%\n\n          -  More than 12 weeks\n\n          -  WBC at least 3,000/mm^3\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n          -  Bilirubin normal\n\n          -  AST or ALT no greater than 2.5 times upper limit of normal\n\n          -  Creatinine normal\n\n          -  Creatinine clearance at least 60 mL/min\n\n          -  No acute ischemia or significant conduction abnormality by EKG\n\n          -  No symptomatic congestive heart failure\n\n          -  No unstable angina pectoris\n\n          -  No cardiac arrhythmia\n\n          -  LVEF greater than 50%\n\n          -  No uncontrolled concurrent illness\n\n          -  No psychiatric illness or social situation that would preclude study\n\n          -  No ongoing or active infection\n\n          -  No prior allergic reaction(s) to compounds of similar chemical or biologic\n             composition to PS-341\n\n          -  No other malignancy within the past 5 years except carcinoma in situ of the cervix or\n             basal cell skin cancer\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective barrier-method contraception\n\n          -  See Chemotherapy\n\n          -  See Disease Characteristics\n\n          -  No more than 1 prior chemotherapy regimen for metastatic disease\n\n               -  High-dose regimen or bone marrow transplantation considered 1 prior regimen\n\n          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and\n             recovered\n\n          -  Prior hormonal therapy for metastatic disease or in adjuvant setting allowed\n\n          -  Prior localized radiotherapy allowed if it does not influence the signal evaluable\n             lesion\n\n          -  At least 4 weeks since prior radiotherapy and recovered\n\n          -  At least 2 weeks since prior minor surgery and recovered\n\n          -  At least 4 weeks since prior major surgery and recovered\n\n          -  No other concurrent investigational agent\n\n          -  No other concurrent investigational or commercial agents or therapies to treat this\n             malignancy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 11, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00025584", 
            "org_study_id": "NCI-2012-02422", 
            "secondary_id": [
                "ID00-308", 
                "N01CM17003", 
                "CDR0000068976"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (bortezomib)", 
                "description": "Given IV", 
                "intervention_name": "bortezomib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "LDP 341", 
                    "MLN341", 
                    "VELCADE"
                ]
            }, 
            {
                "arm_group_label": "Treatment (bortezomib)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bortezomib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "M D Anderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial Of PS-341 In Metastatic Breast Cancer", 
        "overall_official": {
            "affiliation": "M.D. Anderson Cancer Center", 
            "last_name": "Massimo Cristofanilli", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The agent would be of definite interest for further investigation if the associated response rate is at least 30% (p1), and would not be of further interest if the response rate is below 10% (p0).", 
            "measure": "Objective tumor response (CR + PR)", 
            "safety_issue": "No", 
            "time_frame": "Up to 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00025584"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Will be reported using the Kaplan-Meier method with 95% confidence intervals indicated.", 
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "Will be reported using the Kaplan-Meier method with 95% confidence intervals indicated.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "Will be evaluated and descriptive analysis will be performed.", 
                "measure": "Correlation between variations in the serum levels of adhesion molecules and angiogenic factors", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "description": "Will be described in case of lesions amenable to tissue biopsy. The plasma pharmacodynamics of PS-341 as measured by the 20S-proteosome assay, will be used to measured the biological activity of the drug and correlated with response to treatment and variations in biomarkers.", 
                "measure": "Tissue markers of biological activity", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "August 2001", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }, 
    "geocoordinates": {
        "M D Anderson Cancer Center": "29.76 -95.369"
    }
}